Home >Current Issue

Volume: 9, Issue: 2, February, 2019
DOI: 10.7324/JAPS.2019.90212

Research Article

Studying activity and toxicity of different TNF-alpha inhibitors in controlling patients with active ulcerative colitis

Bahir Abdul Razzaq Mshimesh

  Author Affiliations


Ulcerative colitis (UC) is a long-term disorder that associated with overactivation of immunoinflammatory system, ending with ulcer in the large intestine. This study aimed to compare the activity and toxicity of different TNF-alpha inhibitors in a sample of Iraqi patients having active ulcerative colitis. Fifty patients with refractory ulcerative colitis were randomly distributed to either group I (n = 25): on adalimumab injection (160/80 mg) or group II (n = 25): on infliximab injection (5 mg/kg) along the term of induction. Clinical remission was considered as the primary subjective parameter, while clinical response, mucosal healing, and subscores of mild status were regarded as secondary subjective parameters. Fractional Mayo score, inflammatory bowel disease questionnaire (IBDQ), and safety profile were also evaluated. A 24% versus 28% patients were in clinical remission for those receiving adalimumab and infliximab, respectively (p > 0.05), while 48% versus 52% patients were in clinical response for those receiving adalimumab and infliximab, respectively (p > 0.05), and 40% of patients acquired mucosal healing for both adalimumab and infliximab arms (p > 0.05). Scores of physician assessment and rectal bleeding was shown to be markedly higher in infliximab patients (p < 0.05), while those of stool frequency was found to be higher in adalimumab patients (p < 0.05). No significant difference was observed between two arms in the fractional Mayo score and IBDQ index (p > 0.05). Both of the studied biological agents were well-tolerated. As conclusion, the two different TNF-alpha inhibitors were comparable in their clinical remission and safety profile for subjects with active ulcerative colitis.


Ulcerative colitis, clinical remission, safety profile, adalimumab, infliximab.

Citation: Mshimesh BAR. Studying activity and toxicity of different TNF-alpha inhibitors in controlling patients with active ulcerative colitis. J Appl Pharm Sci, 2019; 9(02):087–096.

Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Afif W, Leighton JA, Hanauer SB. An open-label study of Adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 1302–7. https://doi. org/10. 1002/ibd. 20924

Braegger CP, Nicholls S, Murch SH. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339:89-91. https://doi. org/10. 1016/0140-6736(92)90999-J

Chowers Y, Allez M. Efficacy of anti-TNF in Crohn's disease: how does it work? Curr Drug Targets 2010; 11: 138–42. https://doi. org/10. 2174/138945010790309876

Cohen RD, Yu AP, Wu EQ. Systematic review: costs of ulcerative colitis in western countries. Aliment Pharmacol Ther 2010; 31:693-07. https://doi. org/10. 1111/j. 1365-2036. 2010. 04234. x

Colombel JF, Rutgeerts P, Reinisch W. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141:1194–201. https://doi. org/10. 1053/j. gastro. 2011. 06. 054

Colombel JF, Sandborn WJ, Panaccione R. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009; 15:1308–19. https://doi. org/10. 1002/ibd. 20956

Colombel JF, Sandborn WJ, Rutgeerts P. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65. https://doi. org/10. 1053/j. gastro. 2006. 11. 041

Dignass A, Lindsay JO, Sturm A. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6:991–1030. https://doi. org/10. 1016/j. crohns. 2012. 09. 002

Faubion WA Jr, Loftus EV Jr, Harmsen WS. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255–60. https://doi. org/10. 1053/gast. 2001. 26279

Feagan BG, Sandborn WJ, Lazar A. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014; 146:110. https://doi. org/10. 1053/j. gastro. 2013. 09. 032

Ferrante M, Vermeire S, Fidder H. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008; 2: 219–25. https://doi. org/10. 1016/j. crohns. 2008. 03. 004

Finniss DG, Kaptchuk TJ, Miller F. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375:686-95. https://doi. org/10. 1016/S0140-6736(09)61706-2

Frøslie KF, Jahnsen J, Moum BA. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412–22. https://doi. org/10. 1053/j. gastro. 2007. 05. 051

Hanauer SB, Sandborn WJ, Rutgeerts P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-33. https://doi. org/10. 1053/j. gastro. 2005. 11. 030

Hinojosa J, Gomollo´n F, Garcı´a S. Efficacy and safety of short-term Adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007; 25: 409–18. https://doi. org/10. 1111/j. 1365-2036. 2006. 03232. x

Hoentjen F, Van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15: 2067–73. https://doi. org/10. 3748/wjg. 15. 2067

Hudis N, Rajca B, Polyak S. The outcome of active ulcerative colitis treated with adalimumab. Gastroenterology 2009; 136: 683. https://doi. org/10. 1016/S0016-5085(09)63046-8

Humira [Japanese package insert]. Tokyo, Japan: AbbVie GK and Eisai Co, Ltd; 2013.

Irvine EJ, Feagan B, Rochon J. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287–96. https://doi. org/10. 1016/0016-5085(94)90585-1

Jick SS, Lieberman ES, Rahman MU. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthr Rheum 2006; 55:19–26. https://doi. org/10. 1002/art. 21705

Ju¨rgens M, Brand S, Laubender R. Disease activity and pANCA status determine early response to infliximab in ulcerative colitis. Gastroenterology 2009; 136: 680. https://doi. org/10. 1016/S0016-5085(09)63129-2

Langholz E. Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol 2010; 3:77–86. https://doi. org/10. 1177/1756283X10361304

Lee S, Chary M, Salehi I, Bansal R. Immune-mediated adalimumab-induced thrombocytopenia for the treatment of ulcerative colitis. Int J Pharm Pharm Sci 2015; 7 Suppl 7: 456-8.

Lichtenstein GR, Diamond RH, Wagner CL. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210–26. https://doi. org/10. 1111/j. 1365-2036. 2009. 04027. x

Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16:338–46. https://doi. org/10. 1002/ibd. 20997

Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis 2013; 19: 1306–21. https://doi. org/10. 1097/MIB. 0b013e3182807618

Murch SH, Braegger CP, Walker-Smith JA. Location of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34:1705-9. https://doi. org/10. 1136/gut. 34. 12. 1705

Murch SH, Lamkin VA, Savage MO. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7. https://doi. org/10. 1136/gut. 32. 8. 913

Oussalah A, Laclotte C, Chevaux JB. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-center experience. Aliment Pharmacol Ther 2008; 28: 966–72. https://doi. org/10. 1111/j. 1365-2036. 2008. 03811. x

Patil US, Jaydeokar AV, Bandawane DD. Immunomodulators: A pharmacological review. Int J Pharm Pharm Sci 2012; 4 Suppl 1: 30-6.

Peyrin-Biroulet L, Laclotte C, Roblin X. Adalimumab induction therapy for ulcerative colitis with intolerance or response to infliximab: an open-label study. World J Gastroenterol 2007; 13: 2328–32. https://doi. org/10. 3748/wjg. v13. i16. 2328

Rahier JF, Ben-Horin S, Chowers Y. European evidence-based Consensus on the prevention, diagnosis, and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3:47–91. https://doi. org/10. 1016/j. crohns. 2009. 02. 010

Reinisch W, Sandborn WJ, Hommes DW. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut 2011; 60: 780–7. https://doi. org/10. 1136/gut. 2010. 221127

Rubin DT, Dubinsky MC, Panaccione R. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci 2010; 55:1044-52. https://doi. org/10. 1007/s10620-009-0953-7

Rutgeerts P, Sandborn WJ, Feagan BG. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–76. https://doi. org/10. 1056/NEJMoa050516

Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56:453–5. https://doi. org/10. 1136/gut. 2005. 088732

Sandborn WJ, Rutgeerts P, Enns R. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829-38. https://doi. org/10. 7326/0003-4819-146-12-200706190-00159

Sandborn WJ, Rutgeerts P, Feagan BG. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137:1250–60. https://doi. org/10. 1053/j. gastro. 2009. 06. 061

Sandborn WJ, van Assche G, Reinisch W. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257–65. https://doi. org/10. 1053/j. gastro. 2011. 10. 032

Sandborn WJ, Van Assche GA, Thakkar R. Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis. Gastroenterology 2011; 140:263. https://doi. org/10. 1016/S0016-5085(11)61052-4

Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology1994; 106:533-9. https://doi. org/10. 1016/0016-5085(94)90614-9

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625–9. https://doi. org/10. 1056/NEJM198712243172603

Senent S, Martı´n-Arranz M, Merino L. Infliximab in ulcerative colitis: concomitant cytomegalovirus infection, Lifes Quality, PPD positive have an influence on the treatment with infliximab. Gastroenterology 2009; 136: 682. https://doi. org/10. 1016/S0016-5085(09)63139-5

Targan SR, Hanauer SB, van Deventer SJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. N Engl J Med 1997; 337:1029-35. https://doi. org/10. 1056/NEJM199710093371502

Teshima CW, Thompson A, Dhanoa L. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009; 23: 348–52. https://doi. org/10. 1155/2009/180840

Watanabe M, Hibi T, Lomax KG. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis 2012; 6: 160–73. https://doi. org/10. 1016/j. crohns. 2011. 07. 013

William J. Sandborn, Atsushi Sakuraba, Anthony Wang. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin 2016; 32:1233-41. https://doi. org/10. 1185/03007995. 2016. 1168290

Article Metrics

Similar Articles